Scinai Immunotherapeutics Secures Israel Innovation Authority Grant

Ticker: SCNI · Form: 6-K · Filed: 2025-10-06T00:00:00.000Z

Sentiment: bullish

Topics: grant, cdmo, expansion, funding

TL;DR

Scinai gets grant from Israel Innovation Authority to boost CDMO ops.

AI Summary

On October 6, 2025, Scinai Immunotherapeutics Ltd. announced it received a grant from the Israel Innovation Authority. This funding will be used to expand its fill-and-finish Contract Development and Manufacturing Organization (CDMO) capabilities.

Why It Matters

This grant will enhance Scinai's CDMO services, potentially attracting more clients and increasing revenue streams in the biopharmaceutical manufacturing sector.

Risk Assessment

Risk Level: low — The filing is a routine announcement of a grant award, with no immediate negative financial or operational implications.

Key Players & Entities

FAQ

What is the purpose of the grant awarded to Scinai Immunotherapeutics Ltd.?

The grant from the Israel Innovation Authority is intended to expand Scinai's fill-and-finish Contract Development and Manufacturing Organization (CDMO) capabilities.

Who awarded the grant to Scinai Immunotherapeutics Ltd.?

The grant was awarded by the Israel Innovation Authority.

On what date was the grant announcement made?

The announcement of the grant was made on October 6, 2025.

What type of capabilities will be expanded with the grant funding?

The grant will be used to expand fill-and-finish CDMO capabilities.

Is Scinai Immunotherapeutics Ltd. required to file annual reports under Form 20-F or Form 40-F?

Scinai Immunotherapeutics Ltd. indicates it files annual reports under Form 20-F.

From the Filing

0001213900-25-096290.txt : 20251006 0001213900-25-096290.hdr.sgml : 20251006 20251006074524 ACCESSION NUMBER: 0001213900-25-096290 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20251006 FILED AS OF DATE: 20251006 DATE AS OF CHANGE: 20251006 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Scinai Immunotherapeutics Ltd. CENTRAL INDEX KEY: 0001611747 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37353 FILM NUMBER: 251375634 BUSINESS ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 BUSINESS PHONE: 972-8-9302529 MAIL ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: BiondVax Pharmaceuticals Ltd. DATE OF NAME CHANGE: 20140624 6-K 1 ea0260358-6k_scinai.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of October 2025 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ EXPLANATORY NOTE On October 6, 2025, Scinai Immunotherapeutics Ltd. issued a press release announcing an award by the Israel Innovation Authority Grant to expand fill-and-finish CDMO capabilities. A copy of the press release is furnished herewith as Exhibit 99.1. This Report on Form 6-K (other than the paragraph immediately preceding the headline “Serving Early-Stage Biotech Clients Worldwide”) is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-271293 and File No. 333-239344 ) and Form F-3 (File No. 333-274078 and File No. 333-276767 ), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. Exhibit Index Exhibit No. Description 99.1 Press release dated October 6, 2025 . 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: October 6, 2025 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 2 EX-99.1 2 ea026035801ex99-1_scinai.htm PRESS RELEASE DATED OCTOBER 6, 2025 Exhibit 99.1 Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities Grant funds two-thirds of a NIS 1.23 million ($373K) project to strengthen Scinai Bioservices’ small-batch fill and finish capabilities, addressing a critical need among early-stage biotech companies in Israel and abroad JERUSALEM, Oct. 6, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) (“Scinai” or the “Company”), a biopharmaceutical company with a growing boutique contract development and manufacturing organization (CDMO) business unit, Scinai Bioservices, today announced that it has been awarded a non-dilutive grant of approximately NIS 809,000 (about $246,000) from the Israel Innovation Authority (IIA). The grant will fund approximately 66% of a NIS 1.23 million ($373,000) project aimed at acquiring and installing an advanced fill-and-finish system for sterile manufacturing. This investment addresses a major industry gap, as most early-stage biotech companies

View on Read The Filing